MET Exon 14 Alterations in Lung Cancer: Exon Skipping Extends Half-Life

Alexander Drilon1

  • 1Thoracic Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. Weill Cornell Medical College, New York, New York. drilona@mskcc.org.

Insights

MET exon 14 alterations cause oncogenic transformation through mechanisms like exon skipping. These specific MET mutations are clinically targetable with MET-directed therapies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • MET exon 14 alterations represent a diverse group of genetic mutations.
  • These alterations can lead to exon 14 skipping and impaired receptor degradation.
  • Such alterations are implicated in oncogenic transformation.

Purpose of the Study:

  • To investigate the nature of MET exon 14 alterations.
  • To understand the mechanisms leading to oncogenic transformation.
  • To highlight the clinical targetability of these alterations.

Main Methods:

  • Analysis of splice acceptor and donor sites.
  • Assessment of receptor degradation pathways.
  • Evaluation of oncogenic transformation markers.

Main Results:

  • MET exon 14 alterations frequently disrupt splicing.
  • Exon 14 skipping was identified as a key consequence.
  • Impaired MET receptor degradation was observed.
  • Oncogenic transformation was linked to these alterations.

Conclusions:

  • MET exon 14 alterations are a significant driver of oncogenesis.
  • These alterations represent a targetable vulnerability in cancer.
  • MET-directed therapies offer a clinical approach for patients with these mutations.

Related Concept Videos

Exon Recombination02:32

Exon Recombination

The evolution of new genes is critical for speciation. Exon recombination, also known as exon shuffling or domain shuffling, is an important means of new gene formation. It is observed across vertebrates, invertebrates, and in some plants such as potatoes and sunflowers. During exon recombination, exons from the same or different genes recombine and produce new exon-intron combinations, which might evolve into new genes. 
Exon shuffling follows “splice frame rules.” Each exon...
4.3K
RNA Splicing01:32

RNA Splicing

Splicing is the process by which eukaryotic RNA is edited before its translation into protein. The RNA strand transcribed from eukaryotic DNA is called the primary transcript. The primary transcripts that become mRNAs are called precursor messenger RNAs (pre-mRNAs). Eukaryotic pre-mRNA contains alternating sequences of exons and introns. Exons are nucleotide sequences that code for proteins, whereas introns are the non-coding regions. In RNA splicing, introns are removed and exons are bonded...
61.3K
Alternative RNA Splicing02:18

Alternative RNA Splicing

Alternative RNA splicing is the regulated splicing of exons and introns to produce different mature mRNAs from a single pre-mRNA. Unlike in constitutive splicing where a single gene produces a single type of mRNA, alternative splicing allows an organism to produce multiple proteins from a single gene and plays an important role in protein diversity.
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
26.1K
Loss of Tumor Suppressor Gene Functions01:12

Loss of Tumor Suppressor Gene Functions

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
6.2K
Loss of Tumor Suppressor Gene Functions01:12

Loss of Tumor Suppressor Gene Functions

2.0K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

2.9K